WO2002058546A3 - Methods for screening for substances which inhibit fp prostanoid receptor - Google Patents

Methods for screening for substances which inhibit fp prostanoid receptor Download PDF

Info

Publication number
WO2002058546A3
WO2002058546A3 PCT/US2002/000522 US0200522W WO02058546A3 WO 2002058546 A3 WO2002058546 A3 WO 2002058546A3 US 0200522 W US0200522 W US 0200522W WO 02058546 A3 WO02058546 A3 WO 02058546A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inhibit
screening
substances
prostanoid receptor
Prior art date
Application number
PCT/US2002/000522
Other languages
French (fr)
Other versions
WO2002058546A2 (en
Inventor
John W Regan
Original Assignee
Univ Arizona
John W Regan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona, John W Regan filed Critical Univ Arizona
Priority to JP2002558884A priority Critical patent/JP2004531223A/en
Priority to AU2002248322A priority patent/AU2002248322B2/en
Priority to EP02717306A priority patent/EP1429648A4/en
Priority to US10/466,545 priority patent/US20040082013A1/en
Priority to CA002435510A priority patent/CA2435510A1/en
Publication of WO2002058546A2 publication Critical patent/WO2002058546A2/en
Publication of WO2002058546A3 publication Critical patent/WO2002058546A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides mehtods for screening for substances which inhibit the interaction between a FP prostanoid receptor and a compoudn having PGF2α activity, methods for inhibiting the interaction, methods of inhibiting signaling mediated by βbeta-catenin, and methods of treating cancer.
PCT/US2002/000522 2001-01-24 2002-01-24 Methods for screening for substances which inhibit fp prostanoid receptor WO2002058546A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002558884A JP2004531223A (en) 2001-01-24 2002-01-24 Method for screening a substance that inhibits interaction of FP prostanoid receptor with a compound having PGF2α activity and method for treating cancer
AU2002248322A AU2002248322B2 (en) 2001-01-24 2002-01-24 Methods for screening for substances which inhibit FP prostanoid receptor interaction with a compound having PGF2alphaalphaactivity and methods of treating cancer
EP02717306A EP1429648A4 (en) 2001-01-24 2002-01-24 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER
US10/466,545 US20040082013A1 (en) 2002-01-24 2002-01-24 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
CA002435510A CA2435510A1 (en) 2001-01-24 2002-01-24 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2.alpha.alphaactivity and methods of treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26350301P 2001-01-24 2001-01-24
US60/263,503 2001-01-24

Publications (2)

Publication Number Publication Date
WO2002058546A2 WO2002058546A2 (en) 2002-08-01
WO2002058546A3 true WO2002058546A3 (en) 2004-04-08

Family

ID=23002040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000522 WO2002058546A2 (en) 2001-01-24 2002-01-24 Methods for screening for substances which inhibit fp prostanoid receptor

Country Status (5)

Country Link
EP (1) EP1429648A4 (en)
JP (1) JP2004531223A (en)
AU (1) AU2002248322B2 (en)
CA (1) CA2435510A1 (en)
WO (1) WO2002058546A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004212335A1 (en) 2003-02-14 2004-08-26 Merck Serono Sa Piperazine-2-carboxamide derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369470T3 (en) * 1998-09-17 2011-12-01 Hopital Sainte-Justine ANTAGONISTS OF A RECEPTOR COUPLED TO PROTEIN G.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUJINO ET AL: "Delayed reversal of shape change in cells expressing FPb prostanoid receptors", JOURNAL OF BIOPLOGICAL CHEMISTRY, vol. 275, no. 38, 22 September 2000 (2000-09-22), pages 29907 - 29914, XP002973442 *
FUJINO ET AL: "FP prostanoid receptor activation of a T-cell factor/beta-catenin signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 16, 20 April 2001 (2001-04-20), pages 12489 - 12492, XP002973444 *
HONN ET AL: "Eicosanoids and other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 2", 1997, PLENUM PRESS, NEW YORK, article WOODWARD ET AL: "Identification of the FP-receptor as a discrete entity by radioligand binding in biosystems that different functional rank orders of potency in response to prostanoids", pages: 223 - 227, XP002973445 *
PIERCE ET AL: "Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 50, 10 December 1999 (1999-12-10), pages 35944 - 35949, XP002973443 *
STJERNSCHANTZ ET AL: "Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 19, no. 4, 2000, pages 459 - 496, XP001126960 *

Also Published As

Publication number Publication date
WO2002058546A2 (en) 2002-08-01
AU2002248322B2 (en) 2005-06-09
EP1429648A2 (en) 2004-06-23
CA2435510A1 (en) 2002-08-01
EP1429648A4 (en) 2005-03-30
JP2004531223A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2000006085A3 (en) Compounds and methods
WO2003002717A3 (en) Biological activity of ak155
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
WO1998040055A3 (en) Anti-epileptogenic agents
EP2388590A8 (en) PD-1, a receptor for B7-4, and uses thereof
ZA200206265B (en) Screening arrangement.
ZA997680B (en) Catalyst components for the polymerization of olefins.
GEP20104997B (en) Composition comprising anther2 antibodies
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
WO2004074455A3 (en) Fc REGION VARIANTS
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
ZA200007014B (en) Process for the hydroformylation of olefins.
ZA997682B (en) Prepolymerized catalyst components for the polymerization of olefins.
WO2007073497A3 (en) Calcium channel antagonists
MXPA02012410A (en) Method of treating cardiovascular disease.
ZA200203647B (en) Disc brake.
WO2001049713A3 (en) Stabilizing peptides, polypeptides and antibodies which include them
WO2000021513A3 (en) Methods for treating multiple sclerosis
WO2002039118A8 (en) Screening methods for bone morphogenetic mimetics
WO2001059153A3 (en) Method for identifying substances which modulate the activity of hyperpolarisation-activated cation channels
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
AP2004003070A0 (en) The method of treating cancer.
WO2002058546A3 (en) Methods for screening for substances which inhibit fp prostanoid receptor
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002717306

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2435510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002248322

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002558884

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10466545

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002717306

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002248322

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2002717306

Country of ref document: EP